What is it?
 Speech:  
HONcode sites All Web sites HONselect News Conferences Images

Themes:
A B C D E F G H I
J K L M N O P Q
R S T U V W X Y Z
Browse archive:
2008: A J J M A M F J
2007: D N O S

 

     Posting date: 27-Jun-2008

 
Other news for:
Substance-Related Disorders
Substance-Related Disorders
Street Drugs
Resources from HONselect
Drug Helps Heroin Addicts Stay Clean
Those taking buprenorphine lasted almost twice as long until using again, study says

By Robert Preidt

FRIDAY, June 27 (HealthDay News) -- Buprenorphine helps heroin addicts stay clean, and widespread use of the drug could prove to be an effective public health measure, U.S. researchers say.

Their study of 126 detoxified heroin-dependent patients compared 24 weeks of treatment with naltrexone (a standard treatment), buprenorphine and placebo. The researchers compared maintenance of heroin abstinence, prevention of relapse, and reduction of HIV risk behavior in the three groups of patients.

Those taking buprenorphine did best in terms of number of days to first heroin use, days to heroin relapse, and maximum consecutive days of abstinence.

Patients taking buprenorphine lasted almost twice as long until first heroin use compared to those in the naltrexone group, and just over twice as long as those in the placebo group. Patients taking buprenorphine lasted more than twice as long to heroin relapse and had more than twice as many continuous days of heroin abstinence as those taking the placebo.

HIV risk behaviors decreased in all three groups, mainly due to decreased injection drug use, but there were no significant differences between the groups.

"Our findings lend support to the widespread dissemination of treatment with buprenorphine as an effective public health approach to reduce problems associated with heroin dependence," concluded Dr. Richard Schottenfeld, of Yale University School of Medicine, and colleagues.

The study was published in this week's issue of The Lancet .

Health authorities in developing countries should no longer allow only oral naltrexone for the treatment of opioid dependence -- the preferred treatment should be maintenance with either buprenorphine or methadone, Dr. Wayne Hall and Dr. Richard Mattick of Australia wrote in an accompanying commentary.

More information

The National Institute on Drug Abuse has more about heroin .

SOURCE: The Lancet , news release, June 27, 2008

Copyright © 2008 ScoutNews, LLC . All rights reserved.URL:http://www.healthscout.com/template.asp?id=616878

Resources from HONselect: HONselect is the HON's medical search engine. It retrieves scientific articles, images, conferences and web sites on the selected subject.
The list of medical terms above are retrieved automatically from the article.

Disclaimer: The text presented on this page is not a substitute for professional medical advice. It is for your information only and may not represent your true individual medical situation. Do not hesitate to consult your healthcare provider if you have any questions or concerns. Do not use this information to diagnose or treat a health problem or disease without consulting a qualified healthcare professional.
Be advised that HealthDay articles are derived from various sources and may not reflect your own country regulations. The Health On the Net Foundation does not endorse opinions, products, or services that may appear in HealthDay articles.


Home img About us img Contact img MediaCorner img HONewsletter img Ethical policy img Site map
HON Foundation is an NGO in Special Consultative Status with the Economic and Social Council of the United Nations
/News/HSN/616878.html
Last modified:  Aug 26 2008 © HON 2008